{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(10)"],"submitter":["Datta-Mannan A"],"pubmed_abstract":["Imlunestrant (LY3484356) is a next-generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor-positive advanced breast and endometrial cancers. This Phase 1, open-label, 2-part study evaluated the disposition and absolute bioavailability of [<sup>14</sup>C]-imlunestrant in 16 US-based healthy women (aged 36-65 years) of non-childbearing potential. Part 1 participants (N = 8) received an oral dose of 400-mg [<sup>14</sup>C]-imlunestrant solution (100 µCi). Part 2 participants (N = 8) received an oral dose of 2 × 200-mg imlunestrant tablets followed by approximately 45 µg [<sup>14</sup>C]-imlunestrant (approximately 1 µCi) given as a 15-minutes infusion 4 hour later. Blood, fecal, and urine samples were collected. Total radioactivity was primarily eliminated in feces (97.3%) with trace amounts recovered in urine (0.278%), suggesting minimal renal clearance. Imlunestrant accounted for most of the radioactive dose in feces (61.8%), followed by metabolite M2 (20.9%), metabolites M5 + M10 (coeluted), M7, M8, M9, and M11 (5.1% or less for each). Absolute bioavailability of imlunestrant after oral administration relative to intravenous administration was 10.9% based on dose-normalized area under the concentration-time curve from time zero to infinite time. Imlunestrant was well tolerated as an oral solution or as a tablet/intravenous dose. Eight participants reported mild/moderate treatment-related adverse events that resolved by the end of the study."],"journal":["Clinical pharmacology in drug development"],"pagination":["764-775"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12486192"],"repository":["biostudies-literature"],"pubmed_title":["Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open-Label Study."],"pmcid":["PMC12486192"],"pubmed_authors":["Cassidy K","Czeskis B","Yuen E","Rodriguez Cruz V","Datta-Mannan A","Hall S","Shanks E"],"additional_accession":[]},"is_claimable":false,"name":"Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open-Label Study.","description":"Imlunestrant (LY3484356) is a next-generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor-positive advanced breast and endometrial cancers. This Phase 1, open-label, 2-part study evaluated the disposition and absolute bioavailability of [<sup>14</sup>C]-imlunestrant in 16 US-based healthy women (aged 36-65 years) of non-childbearing potential. Part 1 participants (N = 8) received an oral dose of 400-mg [<sup>14</sup>C]-imlunestrant solution (100 µCi). Part 2 participants (N = 8) received an oral dose of 2 × 200-mg imlunestrant tablets followed by approximately 45 µg [<sup>14</sup>C]-imlunestrant (approximately 1 µCi) given as a 15-minutes infusion 4 hour later. Blood, fecal, and urine samples were collected. Total radioactivity was primarily eliminated in feces (97.3%) with trace amounts recovered in urine (0.278%), suggesting minimal renal clearance. Imlunestrant accounted for most of the radioactive dose in feces (61.8%), followed by metabolite M2 (20.9%), metabolites M5 + M10 (coeluted), M7, M8, M9, and M11 (5.1% or less for each). Absolute bioavailability of imlunestrant after oral administration relative to intravenous administration was 10.9% based on dose-normalized area under the concentration-time curve from time zero to infinite time. Imlunestrant was well tolerated as an oral solution or as a tablet/intravenous dose. Eight participants reported mild/moderate treatment-related adverse events that resolved by the end of the study.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T00:22:27.265Z","creation":"2026-05-03T03:12:26.285Z"},"accession":"S-EPMC12486192","cross_references":{"pubmed":["40552410"],"doi":["10.1002/cpdd.1562"]}}